• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Longer-term response to SARS-CoV-2 vaccine in MPN patients: Role of ruxolitinib and disease severity.

作者信息

Auteri Giuseppe, Bartoletti Daniela, Di Pietro Christian, Sutto Emanuele, Mazzoni Camilla, Romagnoli Andrea Davide, Vianelli Nicola, Lazzarotto Tiziana, Cavo Michele, Palandri Francesca

机构信息

IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy; Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy.

IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy.

出版信息

Leuk Res. 2022 May;116:106819. doi: 10.1016/j.leukres.2022.106819. Epub 2022 Mar 3.

DOI:10.1016/j.leukres.2022.106819
PMID:35303626
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8893928/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a11b/8893928/60e5a1df93c2/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a11b/8893928/60e5a1df93c2/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a11b/8893928/60e5a1df93c2/gr1_lrg.jpg

相似文献

1
Longer-term response to SARS-CoV-2 vaccine in MPN patients: Role of ruxolitinib and disease severity.骨髓增殖性肿瘤（MPN）患者对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗的长期反应：芦可替尼的作用和疾病严重程度
Leuk Res. 2022 May;116:106819. doi: 10.1016/j.leukres.2022.106819. Epub 2022 Mar 3.
2
Ruxolitinib does not impair humoral immune response to COVID-19 vaccination with BNT162b2 mRNA COVID-19 vaccine in patients with myelofibrosis.芦可替尼不会损害骨髓纤维化患者对BNT162b2 mRNA新冠疫苗接种的体液免疫反应。
Ann Hematol. 2022 Apr;101(4):929-931. doi: 10.1007/s00277-021-04613-w. Epub 2021 Jul 24.
3
The third dose of mRNA SARS-CoV-2 vaccines enhances the spike-specific antibody and memory B cell response in myelofibrosis patients.mRNA SARS-CoV-2 疫苗的第三剂加强了骨髓纤维化患者的刺突特异性抗体和记忆 B 细胞反应。
Front Immunol. 2022 Sep 29;13:1017863. doi: 10.3389/fimmu.2022.1017863. eCollection 2022.
4
Impaired response to first SARS-CoV-2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib.接受鲁索替尼治疗的骨髓增殖性肿瘤患者对第一剂SARS-CoV-2疫苗接种反应受损。
Am J Hematol. 2021 Nov 1;96(11):E408-E410. doi: 10.1002/ajh.26305. Epub 2021 Aug 12.
5
Holding CoVID in check through JAK? The MPN-approved compound ruxolitinib as a potential strategy to treat SARS-CoV-2 induced systemic hyperinflammation.通过JAK抑制新冠病毒？骨髓增殖性肿瘤（MPN）获批药物鲁索替尼作为治疗SARS-CoV-2诱导的全身炎症反应的潜在策略。
Leukemia. 2020 Jul;34(7):1723-1725. doi: 10.1038/s41375-020-0898-6. Epub 2020 Jun 11.
6
SARS-CoV-2 infection in a pediatrics STAT1 GOF patient under Ruxolitinib therapy-a matter of balance?在接受鲁索替尼治疗的儿科 STAT1 功能获得性患者中感染新型冠状病毒 2 型——平衡问题？
J Clin Immunol. 2021 Oct;41(7):1502-1506. doi: 10.1007/s10875-021-01081-9. Epub 2021 Jun 9.
7
Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.立陶宛血液系统恶性肿瘤患者的 BNT162b2 COVID-19 mRNA 疫苗免疫原性和早期临床结局：一项全国前瞻性队列研究。
Lancet Haematol. 2021 Aug;8(8):e583-e592. doi: 10.1016/S2352-3026(21)00169-1. Epub 2021 Jul 2.
8
Impaired humoral and T cell response to vaccination against SARS-CoV-2 in chronic myeloproliferative neoplasm patients treated with ruxolitinib.接受鲁索替尼治疗的慢性骨髓增殖性肿瘤患者对SARS-CoV-2疫苗接种的体液和T细胞反应受损。
Blood Cancer J. 2022 Apr 22;12(4):73. doi: 10.1038/s41408-022-00651-3.
9
Ruxolitinib for tocilizumab-refractory severe COVID-19 infection.芦可替尼用于治疗对托珠单抗难治的重症COVID-19感染。
Br J Haematol. 2020 Aug;190(4):e198-e200. doi: 10.1111/bjh.16979. Epub 2020 Jul 26.
10
Compassionate use of ruxolitinib in patients with SARS-Cov-2 infection not on mechanical ventilation: Short-term effects on inflammation and ventilation.对未接受机械通气的新型冠状病毒肺炎患者同情用药鲁索替尼：对炎症和通气的短期影响
Clin Transl Sci. 2021 May;14(3):1062-1068. doi: 10.1111/cts.12971. Epub 2021 Jan 27.

引用本文的文献

1
Epidemiology and disease characteristics of myelofibrosis: a comparative analysis between Italy and global perspectives.骨髓纤维化的流行病学及疾病特征：意大利与全球视角的比较分析
Front Oncol. 2024 Jul 24;14:1382872. doi: 10.3389/fonc.2024.1382872. eCollection 2024.
2
Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib.芦可替尼治疗的骨髓增殖性肿瘤（MPN）患者中新冠病毒19疾病的决定因素及新冠病毒19感染后的生存情况
Blood Cancer J. 2023 May 3;13(1):65. doi: 10.1038/s41408-023-00834-6.
3
Ruxolitinib treatment in myelofibrosis and polycythemia vera causes suboptimal humoral immune response following standard and booster vaccination with BNT162b2 mRNA COVID-19 vaccine.

本文引用的文献

1
The Slower Antibody Response in Myelofibrosis Patients after Two Doses of mRNA SARS-CoV-2 Vaccine Calls for a Third Dose.骨髓纤维化患者接种两剂mRNA新冠疫苗后抗体反应较慢，需接种第三剂。
Biomedicines. 2021 Oct 15;9(10):1480. doi: 10.3390/biomedicines9101480.
2
Philadelphia-Negative Chronic Myeloproliferative Neoplasms during the COVID-19 Pandemic: Challenges and Future Scenarios.新冠疫情期间的费城染色体阴性慢性骨髓增殖性肿瘤：挑战与未来展望
Cancers (Basel). 2021 Sep 23;13(19):4750. doi: 10.3390/cancers13194750.
3
Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy.
芦可替尼治疗骨髓纤维化和真性红细胞增多症后，使用BNT162b2 mRNA新冠疫苗进行标准和加强接种会导致体液免疫反应欠佳。
Front Oncol. 2023 Feb 14;13:1117815. doi: 10.3389/fonc.2023.1117815. eCollection 2023.
4
Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis.免疫原性和与血液恶性肿瘤患者在接种 SARS-CoV-2 疫苗和加强针后免疫反应受损相关的风险：一项更新的荟萃分析。
Blood Cancer J. 2022 Dec 23;12(12):173. doi: 10.1038/s41408-022-00776-5.
5
The third dose of mRNA SARS-CoV-2 vaccines enhances the spike-specific antibody and memory B cell response in myelofibrosis patients.mRNA SARS-CoV-2 疫苗的第三剂加强了骨髓纤维化患者的刺突特异性抗体和记忆 B 细胞反应。
Front Immunol. 2022 Sep 29;13:1017863. doi: 10.3389/fimmu.2022.1017863. eCollection 2022.
抗 CD20 治疗的多发性硬化症患者接种 SARS-CoV-2 mRNA 疫苗后的细胞和体液免疫反应。
Nat Med. 2021 Nov;27(11):1990-2001. doi: 10.1038/s41591-021-01507-2. Epub 2021 Sep 14.
4
Impaired response to first SARS-CoV-2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib.接受鲁索替尼治疗的骨髓增殖性肿瘤患者对第一剂SARS-CoV-2疫苗接种反应受损。
Am J Hematol. 2021 Nov 1;96(11):E408-E410. doi: 10.1002/ajh.26305. Epub 2021 Aug 12.
5
Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia.与真性红细胞增多症和原发性血小板增多症患者相比，骨髓纤维化患者对BNT162b2疫苗的反应较低。
J Hematol Oncol. 2021 Jul 29;14(1):119. doi: 10.1186/s13045-021-01130-1.
6
COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies.COVID-19 可引起血液恶性肿瘤患者对 SARS-CoV-2 的抗体应答受损。
Br J Haematol. 2021 Nov;195(3):371-377. doi: 10.1111/bjh.17704. Epub 2021 Jul 16.
7
BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies.BNT162b2 COVID-19 疫苗在血液恶性肿瘤患者中的有效性显著降低。
Am J Hematol. 2021 Oct 1;96(10):1195-1203. doi: 10.1002/ajh.26284. Epub 2021 Jul 14.
8
Impaired antibody response to COVID-19 vaccination in patients with chronic myeloid neoplasms.慢性髓系肿瘤患者对新冠病毒疫苗接种的抗体反应受损。
Br J Haematol. 2021 Sep;194(6):1010-1015. doi: 10.1111/bjh.17644. Epub 2021 Jun 24.
9
Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms.单剂量BNT162b2 mRNA新冠疫苗可在骨髓增殖性肿瘤患者中诱导出高频率的中和抗体及多功能T细胞反应。
Leukemia. 2021 Dec;35(12):3573-3577. doi: 10.1038/s41375-021-01300-7. Epub 2021 May 22.
10
Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution.第五周抗 SARS-CoV-2 BNT162b2 疫苗在接受积极治疗的多发性骨髓瘤和骨髓增生性恶性肿瘤患者中的免疫原性和安全性：来自单一机构的初步数据。
J Hematol Oncol. 2021 May 17;14(1):81. doi: 10.1186/s13045-021-01090-6.